亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

濟南惠誠醫(yī)藥科技有限公司  

生產(chǎn)和銷售各類原料藥及其中間體,如:奧利司他、新利司他、利拉列汀、曲格列汀琥珀酸鹽、苯甲酸阿格列汀、卡格列凈半水合物、磷酸奧司他韋、瑞舒伐他汀鈣及其中間體、磷酸肌酸二鈉鹽、阿地溴銨、噻托溴銨一水合物、依替唑侖、丙戊酸鈉、美沙拉嗪、腎上腺素系列等。

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:趙攀峰
  • 電話:0531-68659623
  • 郵件:sales@hc-pharm.com
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > ***特比萘芬
***特比萘芬
單價 面議對比
詢價 暫無
發(fā)貨 山東濟南市付款后3天內(nèi)
品牌 惠誠
過期 長期有效
更新 2017-07-19 10:00
 
詳細信息

中文名稱: ***特比萘芬

中文同義詞: 特比萘酚;***特比萘酚;特比萘芬***;(E)-N-(6,6-二甲基庚-2--4-炔基)-N-甲基-1-萘甲胺***;特拉萘芬***;***特比萘芬;***特比奈酚;特比萘酚***

英文名稱: Terbinafine Hydrochloride

英文同義詞: (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylaminehydroc;lamosil;n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethanamin(e)-1-naphthalenemethanaminmon;n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethanamin(e)-1-naphthalenemethanaminmonohydrochloride;TERBINAFINE HCL;N-[(2E)-6,6-DIMETHYL-2-HEPTEN-4-YNYL]-N-METHYL-1-NAPHTHALENEMETHANAMINE;TRANS-N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-1-NAPHTHYLMETHYLAMINE HYDROCHLORIDE;(e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethanamine monohydrochloride

CAS: 78628-80-5

分子式: C21H26ClN

分子量: 327.89

EINECS: 245-385-8

用途:***特比萘芬是一種具有廣譜抗真菌活性的丙烯胺類藥物

©2025 濟南惠誠醫(yī)藥科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:11455  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |